\documentclass[twocolumn,twoside]{article}
\makeatletter\if@twocolumn\PassOptionsToPackage{switch}{lineno}\else\fi\makeatother

\usepackage{amsfonts,amssymb,amsbsy,latexsym,amsmath,tabulary,graphicx,times,xcolor}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Following additional macros are required to function some 
% functions which are not available in the class used.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage{url,multirow,morefloats,floatflt,cancel,tfrupee}
\makeatletter


\AtBeginDocument{\@ifpackageloaded{textcomp}{}{\usepackage{textcomp}}}
\makeatother
\usepackage{colortbl}
\usepackage{xcolor}
\usepackage{pifont}
\usepackage[nointegrals]{wasysym}
\urlstyle{rm}
\makeatletter

%%%For Table column width calculation.
\def\mcWidth#1{\csname TY@F#1\endcsname+\tabcolsep}

%%Hacking center and right align for table
\def\cAlignHack{\rightskip\@flushglue\leftskip\@flushglue\parindent\z@\parfillskip\z@skip}
\def\rAlignHack{\rightskip\z@skip\leftskip\@flushglue \parindent\z@\parfillskip\z@skip}

%Etal definition in references
\@ifundefined{etal}{\def\etal{\textit{et~al}}}{}


%\if@twocolumn\usepackage{dblfloatfix}\fi
\usepackage{ifxetex}
\ifxetex\else\if@twocolumn\@ifpackageloaded{stfloats}{}{\usepackage{dblfloatfix}}\fi\fi

\AtBeginDocument{
\expandafter\ifx\csname eqalign\endcsname\relax
\def\eqalign#1{\null\vcenter{\def\\{\cr}\openup\jot\m@th
  \ialign{\strut$\displaystyle{##}$\hfil&$\displaystyle{{}##}$\hfil
      \crcr#1\crcr}}\,}
\fi
}

%For fixing hardfail when unicode letters appear inside table with endfloat
\AtBeginDocument{%
  \@ifpackageloaded{endfloat}%
   {\renewcommand\efloat@iwrite[1]{\immediate\expandafter\protected@write\csname efloat@post#1\endcsname{}}}{\newif\ifefloat@tables}%
}%

\def\BreakURLText#1{\@tfor\brk@tempa:=#1\do{\brk@tempa\hskip0pt}}
\let\lt=<
\let\gt=>
\def\processVert{\ifmmode|\else\textbar\fi}
\let\processvert\processVert

\@ifundefined{subparagraph}{
\def\subparagraph{\@startsection{paragraph}{5}{2\parindent}{0ex plus 0.1ex minus 0.1ex}%
{0ex}{\normalfont\small\itshape}}%
}{}

% These are now gobbled, so won't appear in the PDF.
\newcommand\role[1]{\unskip}
\newcommand\aucollab[1]{\unskip}
  
\@ifundefined{tsGraphicsScaleX}{\gdef\tsGraphicsScaleX{1}}{}
\@ifundefined{tsGraphicsScaleY}{\gdef\tsGraphicsScaleY{.9}}{}
% To automatically resize figures to fit inside the text area
\def\checkGraphicsWidth{\ifdim\Gin@nat@width>\linewidth
	\tsGraphicsScaleX\linewidth\else\Gin@nat@width\fi}

\def\checkGraphicsHeight{\ifdim\Gin@nat@height>.9\textheight
	\tsGraphicsScaleY\textheight\else\Gin@nat@height\fi}

\def\fixFloatSize#1{}%\@ifundefined{processdelayedfloats}{\setbox0=\hbox{\includegraphics{#1}}\ifnum\wd0<\columnwidth\relax\renewenvironment{figure*}{\begin{figure}}{\end{figure}}\fi}{}}
\let\ts@includegraphics\includegraphics

\def\inlinegraphic[#1]#2{{\edef\@tempa{#1}\edef\baseline@shift{\ifx\@tempa\@empty0\else#1\fi}\edef\tempZ{\the\numexpr(\numexpr(\baseline@shift*\f@size/100))}\protect\raisebox{\tempZ pt}{\ts@includegraphics{#2}}}}

%\renewcommand{\includegraphics}[1]{\ts@includegraphics[width=\checkGraphicsWidth]{#1}}
\AtBeginDocument{\def\includegraphics{\@ifnextchar[{\ts@includegraphics}{\ts@includegraphics[width=\checkGraphicsWidth,height=\checkGraphicsHeight,keepaspectratio]}}}

\DeclareMathAlphabet{\mathpzc}{OT1}{pzc}{m}{it}

\def\URL#1#2{\@ifundefined{href}{#2}{\href{#1}{#2}}}

%%For url break
\def\UrlOrds{\do\*\do\-\do\~\do\'\do\"\do\-}%
\g@addto@macro{\UrlBreaks}{\UrlOrds}



\edef\fntEncoding{\f@encoding}
\def\EUoneEnc{EU1}
\makeatother
\def\floatpagefraction{0.8} 
\def\dblfloatpagefraction{0.8}
\def\style#1#2{#2}
\def\xxxguillemotleft{\fontencoding{T1}\selectfont\guillemotleft}
\def\xxxguillemotright{\fontencoding{T1}\selectfont\guillemotright}

\newif\ifmultipleabstract\multipleabstractfalse%
\newenvironment{typesetAbstractGroup}{}{}%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\AtBeginDocument{\let\citet\cite\let\citep\cite}
\usepackage[numbers,sort&compress,numbers,sort&compress]{natbib}


\AtBeginDocument{\let\citet\cite\let\citep\cite}
\newif\ifnokeywords\nokeywordsfalse
\def\abbrvJournalTitle{Future J. Pharm. Health. Sci.}
\def\jrnlurlname{fjphs}
\usepackage{balance}

\makeatletter\input{size10-pointfive.clo}\makeatother%
\definecolor{kwdboxcolor}{RGB}{242,242,242}
\usepackage[hidelinks,colorlinks=true,allcolors=blue]{hyperref}
\linespread{1}                 
\def\floatpagefraction{0.8}

\usepackage[paperheight=11.69in,paperwidth=8.26in,top=1in,bottom=1in,left=1in,right=.75in,headsep=24pt]{geometry}

\usepackage{multirow-custom}

\makeatletter

\def\hlinewd#1{%
  \noalign{\ifnum0=`}\fi\hrule \@height #1%
  \futurelet\reserved@a\@xhline}
\def\tbltoprule{\hlinewd{1pt}\\[-14pt]}
\def\tblbottomrule{\noalign{\vspace*{6pt}}\hline\noalign{\vspace*{2pt}}}
\def\tblmidrule{\hline\noalign{\vspace*{2pt}}}



\let\@articleType\@empty
\let\@journalDoi\@empty
\let\@journalVolume\@empty
\let\@journalIssue\@empty
\let\@crossMarkLink\@empty
\let\@receivedDate\@empty
\let\@acceptedDate\@empty
\let\@revisedDate\@empty
\let\@publishedDate\@empty
\let\@copyrightYear\@empty
\let\@firstPage\@empty
\let\@eISSN\@empty
\let\@pISSN\@empty
\def\eISSN#1{\gdef\@eISSN{#1}}
\def\pISSN#1{\gdef\@pISSN{#1}}
\def\articleType#1{\gdef\@articleType{#1}}
\def\journalDoi#1{\gdef\@journalDoi{#1}}
\def\crossMarkLink#1{\gdef\@crossMarkLink{#1}}
\def\receivedDate#1{\gdef\@receivedDate{#1}}
\def\acceptedDate#1{\gdef\@acceptedDate{#1}}
\def\revisedDate#1{\gdef\@revisedDate{#1}}
\def\publishedDate#1{\gdef\@publishedDate{#1}}
\def\copyrightYear#1{\gdef\@copyrightYear{#1}}
\def\journalVolume#1{\gdef\@journalVolume{#1}}
\def\journalIssue#1{\gdef\@journalIssue{#1}}
\def\firstPage#1{\gdef\@firstPage{#1}}


\def\author#1{%
  \gdef\@author{%
    \hskip-\dimexpr(\tabcolsep)\hskip5pt%
    \parbox{\dimexpr\textwidth-1pt}%
    {\fontsize{11}{13}\selectfont\raggedright #1}%
  }%
}


\usepackage{pharmascope-abs}
\usepackage{caption}
\usepackage{lastpage}
\usepackage{fancyhdr}
\usepackage[noindentafter,explicit]{titlesec}
\usepackage{fontspec}

\setmainfont[%
BoldFont=cambriab.ttf,%
ItalicFont=CAMBRIAI.TTF,%
BoldItalicFont=CAMBRIAZ.TTF]{Cambria.ttf}

\usepackage{qrcode}

%\def\abbrvJournalTitle{Future J. Pharm. Health. Sci.}
\def\jshort{fjphs}

\def\title#1{%
  \gdef\@title{%
%      \vspace*{-20pt}%
       \vspace*{-48pt}
       \ifx\@articleType\@empty\else{\fontsize{10}{12}\scshape\selectfont\hspace{8pt}\@articleType\hfill\mbox{}\par\vspace{2pt}}\fi%
       \minipage{\linewidth}
         \hrulefill\\[-0.7pt]%
         \parbox{.1\linewidth}{\includegraphics[width=4.2cm]{pharmasprings_logo.png}}\hfill
%         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.792\linewidth}{%
         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.729\linewidth}{%
          \begin{center}
          \vskip-4pt 
          \scshape\fontsize{18}{20}\selectfont\journalTitle\hfill\end{center}%
          \vspace*{-16pt}{\vspace*{-3.1pt}\fontsize{8}{9}\selectfont Published by Pharma Springs Publication\hfill  Journal Home Page: \href{https://pharmasprings.com/index.php/\jrnlurlname}{\color{blue}\underline{\smash{https://pharmasprings.com/\jrnlurlname}}}}\hspace*{4pt}\mbox{}}}%
       \par\rule{\linewidth}{1.3pt}%
       \endminipage%
    \par\vspace*{9.2pt}\parbox{.98\linewidth}{\linespread{.9}\raggedright\fontsize{14}{17}\selectfont #1}%
    \vspace*{-8pt}%
  }
}


\setlength{\parindent}{0pt}
\setlength{\parskip}{0.4pc plus 1pt minus 1pt}


\fancypagestyle{headings}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle\ \@copyrightYear;\space\ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    :\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ Pharma Springs Publication\ $|$\space \journalTitle}%
  \fancyfoot[LO]{\fontsize{9.12}{11}\selectfont\textcopyright\ Pharma Springs Publication\ $|$\space \journalTitle}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
}\pagestyle{headings}


                                                         
\fancypagestyle{plain}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}%
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle\ \@copyrightYear;\space\ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    :\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ Pharma Springs Publication\ $|$\space \journalTitle}%
  \fancyfoot[LO]{\fontsize{9.12}{11}\selectfont\textcopyright\ Pharma Springs Publication\ $|$\space \journalTitle}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
  \ifx\@firstPage\@empty\else\setcounter{page}{\@firstPage}\fi
}


\def\NormalBaseline{\def\baselinestretch{1.1}}
\usepackage{textcase}
\setcounter{secnumdepth}{0}

\titleformat{\section}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{13}\selectfont}
{\thesection}
{6pt}
{\MakeTextUppercase{#1}}
[]
\titleformat{\subsection}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsection}
{6pt}
{#1}
[]
\titleformat{\subsubsection}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsubsection}
{6pt}
{#1}
[]
\titleformat{\paragraph}[block]{\NormalBaseline\filright\fontsize{10.5}{10}\selectfont}
{\theparagraph}
{6pt}
{#1}
[]
\titleformat{\subparagraph}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubparagraph}
{6pt}
{#1}
[]

\titlespacing{\section}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsubsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\paragraph}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subparagraph}{0pt}{.5\baselineskip}{.5\baselineskip}

\captionsetup[figure]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}
\captionsetup[table]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}

\def\bibyear#1{#1}
\def\bibjtitle#1{#1}
\def\bibauand{}
\setlength\bibsep{3pt}
\setlength\bibhang{8pt}
\lefthyphenmin = 3
\makeatother
\date{}
\makeatletter
\usepackage{mdframed}
%\usepackage{balance}
\definecolor{unitednationsblue}{RGB}{222,234,246}
\definecolor{cpboxcolor}{RGB}{211,211,211}
\definecolor{citeboxcolor}{RGB}{242,242,242}
\def\printBio{%
  %\noindent\begin{mdframed}[innerbottommargin=7pt,backgroundcolor=unitednationsblue,hidealllines=true,frametitle={ABOUT AUTHORS},innerleftmargin=7pt,leftmargin=2pt,skipabove=1pt,innertopmargin=2pt,innerbottommargin=1pt,skipbelow=1pt]%
  \noindent\begin{mdframed}[innerbottommargin=7pt,backgroundcolor=unitednationsblue,hidealllines=true,frametitle={ABOUT AUTHORS},innerrightmargin=20pt,rightmargin=4,innerleftmargin=7pt,leftmargin=2pt,skipabove=1pt,innertopmargin=2pt,innerbottommargin=1pt,skipbelow=1pt]%
   \@tempcnta=0
    \loop
      \advance \@tempcnta by 1
      \def\aubioCnt{\the\@tempcnta}
      \vskip1pt
%      \noindent\hspace{-2pt}%\fbox{
%     \vspace*{1pt}
      \raisebox{62pt}%{\begin{minipage}[t]{.35\linewidth}%
      \expandafter\ifx\csname authorImage\aubioCnt\endcsname\relax%
       \else%
         \includegraphics[height=60pt,width=60pt]{\csname authorImage\aubioCnt\endcsname}%height=145pt
       \fi%
      %\end{minipage}
      %}%}
      \hskip 4pt%\fbox{
      \raisebox{52pt}{\begin{minipage}[t]{.74\linewidth}%
        {\fontsize{8}{10}\selectfont{\csname authorName\aubioCnt\endcsname\\[5pt]}}
        \fontsize{8}{10}\selectfont\csname authorDetails\aubioCnt\endcsname\\
      \end{minipage}}
%      }
%     \vskip10pt%
    \ifnum\@tempcnta < \theaubio
    \repeat
%     \vspace*{-16.5pt}%
  \end{mdframed}
}


\makeatother


\def\citeauthor{~Balasubramanian~S,
              ~Satheesh~C,
              ~Kalaiselvi~D,
              ~Abinaya~R}
\def\citetitle{The potential of herbal mineral formulation Rasa Parpam (R.P.) as an anti-cervical carcinoma, antitumor and anti-microbiological evaluation (A Siddha medicine for cervical cancer) in in-vitro studies}
\def\copyrightstmt{This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial- ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.}
\publishedDate{}
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Feature enabled:
%citation-style: unsrt
%citation-type: numbered
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\usepackage[flushleft]{threeparttablex}

\usepackage{float}

\begin{document}


\def\RunningAuthor{Balasubramanian S et al.}
\firstPage{281}
\articleType{Original Article}
\receivedDate{02 Jun 2023}
\acceptedDate{26 Jun 2023}
\revisedDate{24 Jun 2023}
\journalVolume{3}
\journalIssue{3}
\journalDoi{fjphs.v3i3.476}
\copyrightYear{2023}
\eISSN{2583-116X}
\journalDoi{fjphs.v3i3.476}
\def\authorCount{4}
\def\affCount{3}

\def\journalTitle{Future Journal of Pharmaceuticals and Health Sciences}

\title{The potential of herbal mineral formulation Rasa Parpam (R.P.) as an anti-cervical carcinoma, antitumor and anti-microbiological evaluation (A Siddha medicine for cervical cancer) in in-vitro studies}
\author{Balasubramanian~S\textsuperscript{*}\textsuperscript{1},  
            Satheesh~C\textsuperscript{2},  
            Kalaiselvi~D\textsuperscript{3}, 
            Abinaya~R\textsuperscript{1}~\\[5pt]{\textsuperscript{1}Shanmuga Siddha Clinic and Laboratories, Thanjavur-613006, Tamil Nadu - India}~\\{\textsuperscript{2}Agash Siddha Wellness Centre and Lab, Chennai- 610010, Tamil Nadu- India}~\\{\textsuperscript{3}Rasi Clinic, Thottiyam. 621215, Trichy Dist - Tamil Nadu - India}}

\begin{abstract}
One of the most fatal diseases of the Twentieth century, cancer is becoming solitary of the majority prevalent diseases of the Twenty-first century. Cervical cancer is a form of carcinoma that affects cervix cells. Cervical cancer is a highly prevalent carcinoma among women under the mandatory age of 35. These objectives were fulfilled to treat cervical cancer with a Siddha medicine formulation, assist those affected by the disease, and investigate to ascertain Rasa Parpam's pharmacological activity (in vitro anticancer activity), as well as to assess the therapeutic effects of Rasa Parpam and to measure antitumor activity against HeLa and SiHa cell lines as well as anticancer activity (MTT assay), and to validate the therapeutic effects of Rasa Parpam. Cervical cancer must be treated appropriately in the medical environment of today. In the MTT experiment, the lowest cell viability was found at an attention of 300 \ensuremath{\mu}g per millilitre, showing 36.24 \ensuremath{\pm}2.854\%. This was tracked by attention of 200 \ensuremath{\mu}g per millilitre, 100 \ensuremath{\mu}g per millilitre also 10 \ensuremath{\mu}g per millilitre, showing 52.86\ensuremath{\pm}3.014, 63.48\ensuremath{\pm}3.264, and 91.59 \ensuremath{\pm}3.386\% respectively. It was discovered that the equivalent IC50 assessment was 139.35 \ensuremath{\pm} 5.863 \ensuremath{\mu}g per millilitre. The formulation R.P. has promised anticancer activity, according to the current study's findings. R.R. is proving to be a potent cervical cancer preventative. It has a variety of pharmacological effects, including antimicrobial and anticancer effects. This cancer treatment is affordable and has no unfavorable side effects. Scientific journals have reported on the anticancer effects of R.P. The anticancer action of R.P. is discussed in this work in the context of several in-vitro with in-vivo studies.
\end{abstract}\def\keywordstitle{Keywords}

\begin{keywords}Rasa Parpam,\newline anti-cervical,\newline Carcinoma,\newline anti-tumour,\newline anti microbiological,\newline in-vitro
\end{keywords}
\twocolumn[ \maketitle {\printKwdAbsBox}]
\makeatletter{\raggedright{\Large$^\ast$}Corresponding Author\par Name:\ Balasubramanian~S~\\ Phone:\ +91 6369814756~\\  Email:\ drshanbala@gmail.com
        \par}\vspace*{-13pt}\hrulefill\par\ifx\@eISSN\@empty\else{\fontsize{12}{14}\selectfont eISSN: \@eISSN\hfill pISSN: \@pISSN}\par\fi% 
        \textsc{DOI:}\ \href{https://doi.org/10.26452/\@journalDoi}{\textcolor{blue}{\underline{\smash{https://doi.org/10.26452/\@journalDoi}}}}\par%
        \vspace*{-12pt}\hrulefill\\[5pt]\hypersetup{allcolors=black}\qrcode[version=4,height=1.5cm]{https://doi.org/10.26452/\@journalDoi}\hypersetup{allcolors=blue} \hspace*{10.5pt}\parbox[t]{5cm}{\raisebox{19pt}{\fontsize{9.12}{10.12}\selectfont Production and Hosted by}\\[-13pt]{{\fontsize{12}{14}\selectfont  Pharmasprings.com \\[-1pt]{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \@copyrightYear\ $|$ All rights reserved.}\\[-8pt]\hspace*{-1pt}\rule{.762\columnwidth}{1.2pt}}}}\hypersetup{allcolors=blue}%{\fontsize{12}{14}\selectfont Pharmasprings.com}\par%
        \makeatother
        
    
\section{Introduction}
A group of disorders known as cancer is characterized by unchecked cell proliferation. Each of the more than 200 different forms of cancer is categorized according to the type of cell that is initially damaged. One of the terrible diseases of this century is cancer. It may lengthen their life and decrease the side effects of radiotherapy and chemotherapy; alternative medicines are becoming more and more popular in this day and age. Clinical signs of cancer include unregulated cell reproduction also gene defects that affect how well cells divide in response to tissue expansion \unskip~\cite{1984295:28380778}.

In 2012, there were 14.2 million new instances of cancer globally, as well as 8.2 million cancer-related deaths, according to representations from the World Health Organization; and breast cancer has exceeded cervical cancer as the tumor that affects women most frequently across the world.

Annually, 80,000 additional cancer instances are recorded in India's National Cancer Registry. For these types of severe ailments, the ancient Indian medicinal sciences of Ayurveda also Siddha describe many beneficial herbal medications.

It is vitally necessary to screen for many different chemicals because of this. Both in-vitro also in-vivo mannequins are used for this objective to conduct systematic pharmacological testing for anticancer compounds. Cervical cancer (CC) is the term used to describe cancer that appears in a woman's cervix. Usual pap tests can detect CC, which often develops little by little over instance with the first look of irregular cells in the cervical beginning to multiply and invade the cervix and its surroundings more thoroughly.

There is no known familial link to cervical cancer. In 99.7\% of instances, high-risk human papillomavirus (HPV) infectious diseases constitute the root reasons for cervical tumor. The bacterium HPV is frequently spread from person to person in the vaginal area through skin-to-skin contact. Eighty percent of sexually active people will contract an HPV infection at some point in their entire lives. Cervical cancer won't occur in most women as an outcome of this, though. Cervical cancer is uncommon, despite the prevalence of HPV infection \unskip~\cite{1984295:28380770}. Cervical cancer comes in two different forms. Adenocarcinomas (5\% {\textendash} 20\%) also squamous cell carcinomas (80\% {\textendash} 90\%).

Mixed carcinoma is the term used to describe cancer that exhibits both types of symptoms. Improved survival rates for cervical cancer depend on early finding and treatment. Most frequently, cervical cancer symptoms appear very late in clinical situations. The most typically recommended treatment intervention in the predetermined scenario for cervical cancer patients with lateral stages is radiation treatment. 

Due to the increased adverse events linked to traditional chemotherapy, it piques the interest of researchers within the field related to carcinoma biology to investigate the alternative medicine of choice, and maybe side-effect-free also the medical benefits are frequently delayed by the tumor cells' recurrent radiotherapy desensitization.

A large number of patients who get chemotherapy have a significant risk of growing anaemia, bone marrow depression, neurodegeneration, stress, depression, etc. Conventional cervical anticancer drugs have a variety of potential side effects. Therefore, discovering a new herbal composition could broaden the application of India's traditional medical systems like Siddha, Ayurvedic and Unani \unskip~\cite{1984295:28380768}. According to the accepted Siddha literature, Rasa Parpam (R.P.) is advised for the treatment of amenorrhea with the inducement of ovulation. 

The medicine R.P. is a venerable, long-used herbal-mineral Siddha preparation that has been prescribed within Siddha texts for some ailments, including cervical cancer. A significant global burden, particularly in developing nations, cervical carcinoma continues to be among the primary factors of cancer-related mortality in women. Particularly with human papillomaviruses (HPVs), viral induction can disrupt the fundamental cellular process that regulates development and also stimulate P\ensuremath{_{I3}}K/AKT/mTOR indicating. It is a prevalent worry because, similar to other malignancies, cervical cancer does not exhibit any warning signals or associated symptoms in the early stages of the disease \unskip~\cite{1984295:28380775}. Key symptoms include acute back discomfort along with vaginal expulsion or bleeding. The majority of people with indications normally have tumors that are in the final phases of growth and have frequently development as well as far for therapeutic treatment as a result.

\textbf{Classification of cancer: }

Cancer can be categorized into five major categories.

Carcinomas, like breast, colon, also lung cancer, are characterized by cells covering internal as well as external body components.

Cells found in the bone marrow, cartilage, fat in the body, fibrous tissue, tissues of the skeletal, and helpful organs ultimately define sarcomas.

Lymphoma is a cancer that may originate in or grow in the lymph nodes of the tissues also immune system.

Leukaemias are tumors that commonly damage the blood cells and start in the bone marrow.

Adenomas are malignancies that develop in the tissues of the thyroid, pituitary, adrenal, and other glands \unskip~\cite{1984295:28380777}.

\textbf{Modern aspect}

\textbf{Anti-cancer drugs/Chemotherapy medications}

Anticancer medications are those that work to prevent cancer. Another name for them is anti-neoplastic medications. 

Cancer-fighting medications are used to slow the growth of malignant cells. The most frequent definition of cancer is unchecked cell development, failure of differentiation, also metastasis, or the tumor's dissemination to additional cells also human organs.

Malignant developments are what cause cancer. Benign growths, on the other hand, stay enclosed and expand inside a clearly defined space. 

Whenever the malignancy has grown throughout the entire body or is likely to do so, medication therapy is used. It is possible to divide them into specialized classes that are cyclic and non-cyclic.

\textbf{Review of Cancer Pharmacology:}

It is now required to keep track of patients' quality of life while they are receiving cancer treatment. The quality of life of cancer patients receiving chemotherapy treatment should be taken into consideration because it has a significant impact on them even after the medications are stopped. Therefore, at this time, the difficult issue is to create quick and innovative ways that might identify and produce compounds that may be useful in treating human cancers \unskip~\cite{1984295:28380774}.

\textbf{In-vitro techniques}

In-vitro cytotoxicity investigations on cancer cell lines use an assortment of cell labelling techniques to inadvertently count the number of live cells that remain after treatment. The primary feature of ideal in-vitro tests for determining cell proliferation and cytotoxicity should be that they are quick, easy, affordable, repeatable, sensitive, safe, and effective for a wide range of viable cell populations without interfering with the compound's evaluation.

\textbf{Benefits: }

Lessen the use of animals

Exploiting several aspects of the cell to test the compound's capacity to destroy the target cell

Capable of processing a lot of chemicals quickly with a small amount

The concentration range employed is comparable to that anticipated for in-vivo research.

\textbf{Negative aspects include: }

A challenge to preserving the culture show negative outcomes for substances that are stimulated subsequent to metabolism also vice versa. Pharmacokinetics cannot be determined.

\textbf{Parpam Pharmaceutical Review }

\textbf{Definitions and terminology}

Parpam is chemical identical to the calyx, which is produced by the calcination procedure. The prescribed medications are processed into parpam using the designated procedures. The origin of the medicines ingested might either be organic or inorganic. As a result, these could be salts, minerals, ores, metals, horns, shells, or secretions \unskip~\cite{1984295:28380792}. 

With few exceptions, most drugs experience chemical oxidation while they exceed the Parpam barrier. Actually, tiny particles are used to make the Parpam, most of which are colloidal in nature. Trituration and effective oxidation are used to produce this ultra-fineness.

Particle fineness is very significant from a physiological perspective. The majority of the metallic and mineral compounds that enter the body through the digestive zone are not taking up by the body because, in most cases, the digestive system's secretions cannot react with these chemicals in a way that makes them absorbed through the organism. When the individual is tic constituent parts of this substance are exceedingly small, the obstacle is solved

The materials are repeatedly ground also heated until they are reduced to distinct chemical complexes, or at the very least, tiny particles that can be performed upon through the body in addition to absorbed and assimilated into the tissues.
    
\section{Method and Materials }
\textbf{Research on the medication}

\textbf{Preference of medication}

Rasa Parpam is a solitary of the herbal-mineral Siddha formulations and boosts the therapeutic impact. By evaluating pharmaceuticals and illuminating the structural elements of the formulation of Rasa Parpam.

\textbf{Ingredients}


  
  \begin{enumerate}
  \item \relax Purified Elemental Mercury (VaalaiRasam): 35 grams 
  \item \relax Sulfur (Gandhagam): 35 grams 
  \item \relax Urgineaindica of Indian squill (Kattuulli): 35grams 
  \item \relax Plumbagozeylanica, known as Kodiveli
  \end{enumerate}
  \textbf{Acquisition of the raw drug:}

In Chennai, Tamil Nadu, at Parry's Corner, the R.N. Rajan Country crude drug store sold sulfur, red sulfide of mercury, and Urgineaindica. The raw ingredients were categorized and recognized by Botanists also Gunapadam  specialists at Government Siddha Medical College, Arumbakkam, Chennai. The Kolli Hills in the Namakkal District are where kattuulli (Urgineaindica) was harvested. Each raw material has a sample maintained in our laboratory as a specimen for future endeavors. 

\textbf{Drug preparation for purity}

According to Siddha literature, all of the basic components were purified.

\textbf{Vaalairasam (treated elemental mercury)}

The roots of Plumbagozeylanica, known as Kodiveli, were thoroughly mashed into a cream, placed inside a clay pot, and allowed to dry. Another clay pot was used to hold a 245-gm (7-palam) lingam (Cinnabar), and the mouth was sealed with Kodiveli. Then the clay-pasted fabric was used to plug their mouths. This equipment was put inside the earthen stove also burned with firewood for three hours. In the upper pot, pure elemental Mercury was acquired. In the end, it was gathered and used to make Rasa Parpam  \unskip~\cite{1984295:28380782}.

\textbf{Sulfur}

An iron spoon is filled with sulfur. The mixture is poured at an angle into the cow's milk after adding just a bit of a dairy cow's buttery. The butter inside the scoops has been warned till everything dissolves. To obtain pure sulfur, this process must be performed seven times. When using fresh milk, always do so.

Ghee was heated with sulfur. Pour it into the milk once it has begun to melt. To obtain purified sulfur, repeat the process seven times. When using fresh milk, always do so \unskip~\cite{1984295:28380789}.

\textbf{Urgineaindica{\textendash}(Kattuulli)}

The dust was taken out \unskip~\cite{1984295:28380780}.

\textbf{Notes on the pharmaceuticals used}

The pharmaceuticals consumed should be pure, and those that need to be purified must go through Siddha Science's purification process.

The substances consumed need to be appropriately identified.

Extreme care should be taken when handling molten metal's and placing them with particular liquids to prevent disasters.


\begin{table*}[!htbp]
\caption{\boldmath {Presents the microbiological contamination of RP results. Below is a table with the data} }
\label{tw-d47f9f19934f}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.1868\linewidth-2\tabcolsep}p{\dimexpr.2568\linewidth-2\tabcolsep}p{\dimexpr.21020000000000003\linewidth-2\tabcolsep}p{\dimexpr.34620000000000005\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Trial & Outcome & Pattern & As directed by AYUSH/WHO\\
\tblmidrule 
Microbial activity &
  Lacking &
  NMT105CFU/g &
  \multicolumn{1}{p{\dimexpr(.34620000000000005\linewidth-2\tabcolsep)}}{\multirow{2}{\linewidth}{As directed by AYUSH  norms}}\\
Fungi activity &
  Lacking &
  NMT103CFU/g &
  \\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Specific Pathogens on R.P. Results} }
\label{tw-c3cd137f08e0}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.2234\linewidth-2\tabcolsep}p{\dimexpr.2268\linewidth-2\tabcolsep}p{\dimexpr.25330000000000005\linewidth-2\tabcolsep}p{\dimexpr.2965\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Organism & Pattern & Outcome & Technique\\
\tblmidrule 
E-coli &
  Absent &
  Absent &
  As directed by AYUSH \mbox{}\protect\newline specification\\
K. pneumonia &
  Not there &
  Not there &
  \\
P. aeruginosa &
  Not there &
  Not there &
  \\
S. aureus &
  Not there &
  Not there &
  \\
B. cereus &
  Absent &
  Absent &
  \\
C. albicans &
  Absent &
  Absent &
  \\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {The region of inhibition in mm also the percentage of standard medicines} }
\label{tw-4a9b75959e56}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.1044\linewidth-2\tabcolsep}p{\dimexpr.2955\linewidth-2\tabcolsep}p{\dimexpr.24\linewidth-2\tabcolsep}p{\dimexpr.14950000000000001\linewidth-2\tabcolsep}p{\dimexpr.2106\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}S.No & Trial Organism & \multicolumn{2}{p{\dimexpr(.3895\linewidth-2\tabcolsep)}}{Activation region width in millimetres} & \%   of the RP-inhibition region that average\\
\rowcolor{kwdboxcolor} &  & StandardControl \mbox{}\protect\newline (Bacteria) Ciprofloxacin & Rasa Parpam & \\
\tblmidrule 
1 &
  E. coli &
  28-33 &
  16-23 &
  60-70\\
2 &
  P. aeruginosa &
  30-34 &
  15-19 &
  46-50\\
3 &
  S. aureus &
  28-31 &
  15-19 &
  53-61\\
4 &
  K. pneumonia &
  26-30 &
  11-14 &
  42-47\\
5 &
  B. cereus &
  24-28 &
  9-13 &
  34-45\\
6 &
  C. albicans &
  14-17 (Clotrimazole) &
  13-16 &
  85-89\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {A description of a particular media and its acronym} }
\label{tw-9a13ccd5ad74}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.4397\linewidth-2\tabcolsep}p{\dimexpr.3466\linewidth-2\tabcolsep}p{\dimexpr.2137\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Microorganism & Abbreviation & Media\\
\tblmidrule 
E-coli &
  EC &
  EMB Agar\\
K. pneumonia &
  K.P. &
  Deoxycholate agar\\
P. aeruginosa &
  PA &
  CetrimideAgar\\
S. aureus &
  SA &
  Mannitolsalt agar\\
B. cereus &
  B.C. &
  Deoxycholate agar\\
C. albicans &
  CA &
  EMB Agar\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{Pesticide Remains was done and Test for fla toxins were done}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Fungal with bacterial dilution} }
\label{tw-c2dd31c84cf2}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.4097\linewidth-2\tabcolsep}p{\dimexpr.2736\linewidth-2\tabcolsep}p{\dimexpr.3167\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Bacteria & Dilution & Outcomes\\
\tblmidrule 
Microorganisms &
  10-4 &
  7\\
Microorganisms &
  10-6 &
  6\\
Fungus &
  10-3 &
  Zero\\
Fungus &
  10-2 &
  Zero\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {The impact of the experimental medication R.P. on the HeLa (cervical carcinoma) tissue line's cell mortality} }
\label{tw-1c81270be3d9}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.2104\linewidth-2\tabcolsep}p{\dimexpr.44959999999999994\linewidth-2\tabcolsep}p{\dimexpr.34\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}S. No & Attentiveness in \ensuremath{\mu}g per millilitre & \% Tissue mortality\\
\tblmidrule 
1 &
  10 &
  5.10\ensuremath{\pm} 3.173\\
2 &
  100 &
  31.82\ensuremath{\pm}3.074\\
3 &
  200 &
  42.63\ensuremath{\pm} 3.521\\
5 &
  300 &
  59.28\ensuremath{\pm} 2.985\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Rasa Parpam's anticancer effects on the HeLa lines of cell} }
\label{tw-3f74366b1c9d}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.1708\linewidth-2\tabcolsep}p{\dimexpr.2319\linewidth-2\tabcolsep}p{\dimexpr.1973\linewidth-2\tabcolsep}p{\dimexpr.20\linewidth-2\tabcolsep}p{\dimexpr.20\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}S. No. & Attentiveness (\ensuremath{\mu}g/ml) & Dilutions & Absorbance (S.D) & Tissue lines feasibility (\%)\\
\tblmidrule 
1 &
  300 &
  Efficient &
  0.986 &
  38.14\\
2 &
  200 &
  1:1 &
  1.108 &
  43.08\\
3 &
  100 &
  1:2 &
  1.123 &
  51.34\\
4 &
  10 &
  1:4 &
  1.224 &
  58.86\\
5 &
  Cell control &
  - &
  1.436 &
  100\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\bgroup
\fixFloatSize{images/34a9f71f-e12b-4286-baf2-25a41757065c-upicture1.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/34a9f71f-e12b-4286-baf2-25a41757065c-upicture1.png}{\includegraphics{images/34a9f71f-e12b-4286-baf2-25a41757065c-upicture1.png}}{\includegraphics{34a9f71f-e12b-4286-baf2-25a41757065c-upicture1.png}}
\makeatother 
\caption{\boldmath {Plate 5 RP, Estimated at single concentration of 200 \ensuremath{\mu}l}}
\label{f-aa5ac7dfab9c}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/1aa80d19-fe3b-4884-9d4e-f99304ce6282-upicture2.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/1aa80d19-fe3b-4884-9d4e-f99304ce6282-upicture2.png}{\includegraphics{images/1aa80d19-fe3b-4884-9d4e-f99304ce6282-upicture2.png}}{\includegraphics{1aa80d19-fe3b-4884-9d4e-f99304ce6282-upicture2.png}}
\makeatother 
\caption{\boldmath {E.coli specific medium in a culture plate}}
\label{f-4df957a92980}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/c9d82650-d75a-4cd3-9f71-fa9104922d85-upicture3.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/c9d82650-d75a-4cd3-9f71-fa9104922d85-upicture3.png}{\includegraphics{images/c9d82650-d75a-4cd3-9f71-fa9104922d85-upicture3.png}}{\includegraphics{c9d82650-d75a-4cd3-9f71-fa9104922d85-upicture3.png}}
\makeatother 
\caption{\boldmath {K.pneumonia {\textendash} specific medium on a culture plate}}
\label{f-bbe97a0b11b9}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/dffb474f-617c-4cf6-98ea-1756ce32fdab-upicture4.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/dffb474f-617c-4cf6-98ea-1756ce32fdab-upicture4.png}{\includegraphics{images/dffb474f-617c-4cf6-98ea-1756ce32fdab-upicture4.png}}{\includegraphics{dffb474f-617c-4cf6-98ea-1756ce32fdab-upicture4.png}}
\makeatother 
\caption{\boldmath {S.aureus specific medium on a culture plate}}
\label{f-b8074772f16c}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/30fa22ed-8df2-4286-9478-251d3426b9d8-upicture5.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/30fa22ed-8df2-4286-9478-251d3426b9d8-upicture5.png}{\includegraphics{images/30fa22ed-8df2-4286-9478-251d3426b9d8-upicture5.png}}{\includegraphics{30fa22ed-8df2-4286-9478-251d3426b9d8-upicture5.png}}
\makeatother 
\caption{\boldmath {P. aeruginous specific media on a culture plate}}
\label{f-b8fa3c72c0ee}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/40ba7d2c-29c8-4142-a123-413339c5ac7e-upicture6.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/40ba7d2c-29c8-4142-a123-413339c5ac7e-upicture6.png}{\includegraphics{images/40ba7d2c-29c8-4142-a123-413339c5ac7e-upicture6.png}}{\includegraphics{40ba7d2c-29c8-4142-a123-413339c5ac7e-upicture6.png}}
\makeatother 
\caption{\boldmath {B. cereus specific media on a culture plate}}
\label{f-31a4ff708143}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/bd762e00-06c7-429d-991c-f2b4e6d1389e-upicture7.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/bd762e00-06c7-429d-991c-f2b4e6d1389e-upicture7.png}{\includegraphics{images/bd762e00-06c7-429d-991c-f2b4e6d1389e-upicture7.png}}{\includegraphics{bd762e00-06c7-429d-991c-f2b4e6d1389e-upicture7.png}}
\makeatother 
\caption{\boldmath {C. albicans specific media on a culture plate}}
\label{f-d26ca85c7d6b}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/d6684137-cf2b-42ad-9f95-649558c5d690-upicture8.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/d6684137-cf2b-42ad-9f95-649558c5d690-upicture8.png}{\includegraphics{images/d6684137-cf2b-42ad-9f95-649558c5d690-upicture8.png}}{\includegraphics{d6684137-cf2b-42ad-9f95-649558c5d690-upicture8.png}}
\makeatother 
\caption{\boldmath {Cell line HeLa underwent incubation using various test drug concentrations}}
\label{f-e5728c3909d9}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/797e61a2-b741-4761-b7ef-3f8c2d5c9585-upicture9.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/797e61a2-b741-4761-b7ef-3f8c2d5c9585-upicture9.png}{\includegraphics{images/797e61a2-b741-4761-b7ef-3f8c2d5c9585-upicture9.png}}{\includegraphics{797e61a2-b741-4761-b7ef-3f8c2d5c9585-upicture9.png}}
\makeatother 
\caption{\boldmath {RP's percentage-based suppression of the HeLa lines of cell viability}}
\label{f-479c5e7c04cf}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/c45672f7-fe8a-4d9c-8bb9-0e78491b9dd2-upicture10.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/c45672f7-fe8a-4d9c-8bb9-0e78491b9dd2-upicture10.png}{\includegraphics{images/c45672f7-fe8a-4d9c-8bb9-0e78491b9dd2-upicture10.png}}{\includegraphics{c45672f7-fe8a-4d9c-8bb9-0e78491b9dd2-upicture10.png}}
\makeatother 
\caption{\boldmath {Analysis of the in vitro lactate dehydrogenase discharge from HeLa tissues}}
\label{f-b7c49efdefeb}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/5bd7a99e-1854-4179-9bb1-a214d853f5c0-upicture11.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/5bd7a99e-1854-4179-9bb1-a214d853f5c0-upicture11.png}{\includegraphics{images/5bd7a99e-1854-4179-9bb1-a214d853f5c0-upicture11.png}}{\includegraphics{5bd7a99e-1854-4179-9bb1-a214d853f5c0-upicture11.png}}
\makeatother 
\caption{\boldmath {Analysis of the in vitro lactate dehydrogenase discharge SiHa tissues}}
\label{f-35869ddb308c}
\end{figure}
\egroup
\textbf{The general preparation process}

Along with other pills, liquids, or otherwise decoctions, pharmaceuticals are pulverized according to a precise formulation. The final product is cut into little, round, light cakes that are likewise dehydrated. They are utilized in melting once they have been completely dry up. 

The components are placed in the clay disc mentioned earlier that has been prepared for calcinations, enveloped by inverting one more disc, and the rim is sealed with a fabric ribbon which was already wet clay smeared on one side of the plate. This results in a crucible-like capsule. When the seal on the capsule has dried, it is placed inside the furnace for the calcinations \unskip~\cite{1984295:28380776}.

In Tamil, the kiln is referred to as a pudam and is built by digging a trench under the soil that is the proper size, as well as the fuel worker put the necessary quantity of dung from cow's bars into it. The pit's inside should be bricked in so that it can be used repeatedly.

The pit is filled with 75\% of the required amount of dung cakes before the capsule (or capsules) are placed centrally. The additional manure bars are positioned over it, and the peak is roughly shaped like a dome. 

The dung bar below the burning charcoal catches fire when it is positioned on the arena, and the fire then evenly spreads throughout the area.

Until the entire of dung bars are burned and reduced to ashes, the kiln will continue to burn for an extended period of time. The ashes are carefully brought out of the kiln when it's completely cooled, and the capsule is removed without destroying the seal. The ashes are completely swept off the capsule's exterior with a brush subsequently; the protective covering is removed by scraping it off.

After extracting the capsule's contents, any leftovers sticking to its surfaces are combed away with a lightly scraped brush. It may be necessary to repeat the grinding, dewatering, and calcining processes several times, otherwise at the very least as many times as specified in the guidelines, for the material to completely transform into the Parpamphase.Though, the calcinations are carried out again and again until the desired outcome is achieved. However, even if an acceptable Parpamis obtained after only a few calcinations, the procedure should be replicated in those cases where the total number of calcinations is clearly defined \unskip~\cite{1984295:28380790}.

\textbf{Technique}

To make the paste for the trial medicine, 35 grams of Indian squill with pure sulfur were collected, added to a granite mortar, as well as thoroughly mashed. It is manufactured in the form of a pellet. The pellet had been stored in an earthenware container; also the Kuzhipudakaruvi apparatus was used to calcinate the material to produce medicinal oil. This oil from Pudam (Kuzhipudathylam) was combined with VaalaiRasam also left outside in the sun for a day. The material was also dried. This formed a pellet after being crushed with the prior oil. Blocks were seized and also cut into bits about the dimension of betel nuts. 50 \% of the brick fragments were placed in an earthen container with a circular bottom. The pellet was preserved on top of the salt, which was piled with 1.3 lit(1 padi)of salt above the brick fragments \unskip~\cite{1984295:28380795}. The jar was wrapped with eight layers of clay-pasted fabric, covered with a clay dish, and heated over an elevated flame with firewood (Kaadakkini). The enveloping dish was then taken off. The upper clay dish contained the sublimate. Finally, the Parpam was gathered and thoroughly ground. The Rasa Parpam was gathered and preserved in an airtight vessel. The RasaParpam bears the designation R.P.

Administration Route: Oral

Dosage: 488mg- (Panavedaialavu)

Adjuvant:  Jiggery from Palm

Indication: Tumor, Cervical cancer, inguinal bubo, Abscess.

\textbf{Storage}

Parpams are typically kept in glass bottles for storage. Glass vials are utilized for smaller packing. While equipment exists for encapsulation may also be performed. Preparations should be kept and stored in containers with the appropriate labels. If properly maintained, they are believed to keep their power for 100 years \unskip~\cite{1984295:28380772}.

\textbf{Anti-microbiological action}

There is hurry for the discovery of new medications that are not reliant on artificial anti-microbial mediators for managing the symptoms of recurrent cervical malignancy ailment due to the rising appearance of microorganism strains that are resistant to drugs in traditional anticancer therapies. In this current investigation, as a fraction of effectiveness exposition of R.P. in cervical malignancy states, antimicrobial action against the MTCC isolates of E. coli, P. aeruginosa, K. pneumonia, S. aureus, B. cereus  also C. albicans was observed by the Hole plate diffusion technique \unskip~\cite{1984295:28380796}.

All of the earlier mentioned pathogens displayed 50\% or otherwise additional responsively to R.P. as contrasted to Ciprofloxacin regulation during the screening of action against them. The test medicine was more effective against the germs of P. aeruginosa, E. coli, and also K. pneumonia. In this investigation, a common drug served as a control. For the anti-bacterial trial, ciprofloxacin was employed, and for the anti-fungal research, Candid-BTM cream (clotrimazole-betamethasone), a commercial product, was used.

R.P. also showed an essentially equivalent effect against C. albicans compared with the usual Clotrimazole, as well as beclomethasone (Candid-BTM). The research confirms that the Siddha formulations R.P. employed in cervical cancer treatment has anti-microbial efficacy against a number of infection-causing bacteria's as a valuable complement.

Concerning both gram-negative with gram-positive organisms, the Siddha formulations, R.P., demonstrated reasonable broad-spectrum antibacterial efficacy (Figures~\ref{f-4df957a92980}, \ref{f-bbe97a0b11b9}, \ref{f-b8074772f16c}, \ref{f-b8fa3c72c0ee}, \ref{f-31a4ff708143} and~\ref{f-d26ca85c7d6b}), with E. coli bacteria exhibit a superior responsiveness region of about 70\%, when compared to the traditional positive regulation Ciprofloxacin (Ranbaxy). Additionally, the trial drug's sensitivity to the other species indicated in Table~\ref{tw-d47f9f19934f}  was around 50\% higher than ciprofloxacin. The trial medicine, R.P., has an extremely similar C. albicans fungal responsiveness to Clotrimazole as well as Beclomethasone in C. albicans is about 88\% (Candid-BTM). Therefore, this medication may also be beneficial in treating pelvic inflammatory diseases when used to treat cervical cancer issues owing to their antimicrobial efficiency. IIT Madras, Tamil Nadu, was where an antimicrobial study was carried out \unskip~\cite{1984295:28380784}.

\textbf{Breeding of pathogens}

E. coli, K. pneumoniae, S. aureus, P. aeruginosa, B. cereus, and C. albicans comprised the microbes species included in the effectiveness assessment. These have been procured from the MTCC, Chandigarh, India, also subcultures in accordance with the guidelines and standard operating procedures established by the National Committee for Clinical Laboratory norms. On nutrient agar gradients, bacterial cultures of stock have been maintained about 4 \ensuremath{^\circ}C. (Hello, Mumbai media)

\textbf{Purification and sterilization}

The glassware used in this investigation was cleaned using a cleaning solution before being sterilized for three hours in a hot air oven set to 180 \ensuremath{^\circ}C. The complete nutrition media was autoclave sterilized for over 15{\textendash}20 minutes at 121\ensuremath{^\circ}C and 15 psi.

\textbf{Creation of trial medicine specimen }

To make the trial sample RPsquat viscous and easier to handle with a pipette, pure water from distillation in the amount of two ml was combined. To establish an identical fluid, the test specimen was subsequently processed with roughly thirty minutes

\textbf{Sterility Test for RP }

The trial formulation underwent a preliminary sterility assessment using the disc plate technique. A newly arranged nutrient agar media was placed inside the sterile disc, which was also used. Because of the experimental mixture's colloidal environment, cleaning or other types of streaks are not possible. The disc was coated with a 200 \ensuremath{\mu}l concentration of the trial formulation, which was then incubated for 48 hours while being checked on sporadically. After incubation, the incubated sheet was watched for 12, 24, also 48 hours, but neither a single organism nor a colony could be discovered growing on the formulation \unskip~\cite{1984295:28380793}. (Figure~\ref{f-aa5ac7dfab9c})

\textbf{Creation of the inoculums}

Using test tubes containing Mueller-Hinton broth (MHB) screening microorganisms, cells from the reserve cultures were transferred in a loop also for mildew, using Sabouraud dextrose broth (SDB) and 24 hours of culture at 37 \ensuremath{^\circ}C also 25\ensuremath{^\circ}C, correspondingly, to create the lively cultures for the tests. To achieve optical densities for bacteria that are equivalent to 2.0x10\ensuremath{^{6}} colony-forming units (CFU/ml) also for fungal strains, the colonies suffered at 2.0\ensuremath{\bullet} 105 spores/ml by new Mueller-Hinton with Sabouraud dextrose broth \unskip~\cite{1984295:28380779}. Method using a hole plate. 

\textbf{Microbial Stack Sterility Evaluation by Pour Plate Technique}

Because it allowed for the counting of live cells, the plate count method was among the most frequently utilized procedures. It also serves to ascertain the product's sterility. The characteristic pattern of colonies in the contaminated or unsterile sample (formulation), which promotes the multiplication of the organism when it comes into exposure to the nutrient-rich environment was used to identify the spread of the organism after the necessary duration of incubation. The colony-forming units (CFUs) are used to identify the colonies \unskip~\cite{1984295:28380788}.

\textbf{Dilution:}

The diluents, also known as the dilution blank, are a big volume of sterile water or saline that is combined with a small measured volume. Usually, dilutions are made in multiples of that number of ten \unskip~\cite{1984295:28401883}. The procedure for a lone dilution was the following:

The sample's dimensions are the specimen's whole volume, with diluents being equivalent to dilution.

\textbf{Method/Procedure}

Before the trial sample was added, 15 mL of molten, 45\ensuremath{^\circ}C-heated agar was placed on a sterile Petri plate. The specimen also agars were entirely mixed by tilting with swirling the plate. Agar was permitted to turn into a sticky substance untouched. (Roughly ten minutes). The discs were then turned over and kept at 37 degrees Celsius for 24{\textendash}48 hours before being left there for an additional 72 hours to observe fungal development. The organism's colonies were then counted, and their CFU values were computed. \unskip~\cite{1984295:28380786}

The diluting samples should be marked with the numbers 10\ensuremath{^{-1}} through 10\ensuremath{^{-7}}. By mixing 1 millilitre of the sample specimen with 9 ml of the dilution sample (10)\ensuremath{^{-1}}, you can create an initial dilution by diluting the initial specimen 10 times. To ensure an even distribution of the organisms, roll the tube back as well as forth connecting hands. Using a sterile, fresh, 1 cc pipette, make one hundred dilutions from the original specimen by transferring 1 ml of the solution to the dilution with blank 10\ensuremath{^{-2}}, starting with the first dilution.

With one new, sterilized pipette, the initial specimen should be 1000 times diluted by adding 1   cc from the 10\ensuremath{^{-2}} suspension to the 10\ensuremath{^{-3}} dilution blank. Repeat this process as necessary, using a new, sterile pipette each time, until the initial specimen is dissolved in 10,000,000 instances. Transfer 1 ml of the suspension from the appropriate dilutions to sterile Petri dishes while moving the pipettes as needed. For each dilution, three Petri dishes should be utilized. Each Petri plate containing the diluted sample should contain 15 ccs of the nutritional medium that has been melted and chilled to 45 \ensuremath{^\circ}C. To evenly disperse the cells throughout the media, gently rotate the contents of each plate. Let the plates solidify. These plates need to be incubated over a period of 24 to 48 hours at 37 degrees Celsius while being turned frequently.

\textbf{Microbiological contamination results: }

The above chart establishes that the test substance, R.P., was devoid of live microorganisms. As a result, sterile medicine preserves the test drug's effectiveness and strength.

\textbf{Observation}

Watch and observe the appearance or colonies of microbes on every single plate. Calculate the initial suspension's bacterial density using the formula below:

Colonies present (the mean of 5 plates). 

Organisms per millimeter = Plating volume x dilution

\textbf{Outcomes}

None of the plates where the R.P. was infected had colonies or other signs of growth.

\textbf{Findings for a Particular Pathogen}

E. coli, S. aureus, also P. aeruginosa were specifically screened for in the test drug R.P., but no traces of any of the four pathogens were found. Figures~\ref{f-4df957a92980}, \ref{f-bbe97a0b11b9}, \ref{f-b8074772f16c}, \ref{f-b8fa3c72c0ee}, \ref{f-31a4ff708143} and~\ref{f-d26ca85c7d6b}  shows culture plates where the findings are listed in Table~\ref{tw-c3cd137f08e0}. 

\textbf{Statistical evaluation}

The statistics were provided as mean \ensuremath{\pm} S.D., and each experiment was run in duplicate also replicated at least six instances. A one-way ANOVA was used in the statistical investigation using the Sigma Stat 3.5 programs (Origin Pro 8.0) from Systat program, Inc. P assessments below 0.05 were taken to be as statistically significant in statistical terms. The value shown in the Table~\ref{tw-4a9b75959e56}  represents the result of three tests, one for each formulation and one for each organism. The region diameter is defined as an array of millimeter values, from lowest to maximum \unskip~\cite{1984295:28380781}.

\textbf{Methodology for Specific Pathogen}

A load of antimicrobials (Bacterial as well as fungal load) availability in Rasa Parpam [Tables~\ref{tw-9a13ccd5ad74} and~\ref{tw-c2dd31c84cf2}].

\textbf{Analysis}

It is the only potentially contaminated ingredient utilized in the production of Siddha herbal-mineral remedies. In addition to causing degeneration, microbial contamination of herbal medicines also lowers their potency.

The harmful effect created by bacteria renders herbal medicines ineffective for human intake since the contaminated medications may result in the growth of undesirable diseases rather than curing the condition.

\textbf{Anticancer as well as antitumor efforts promote tissue growth}

Female cancer cell lines of the cervical gland, such as SiHa and HeLa, were employed in this research, a contribution made by the Pune-based National Centre for Cell Science, India. Moreover, Dulbecco's adjusted Eagle media (Gibco, Invitrogen) was used for their incubation \unskip~\cite{1984295:28380783}.

\textbf{Calculation of Apoptosis}

Each cell variety was seeded using 96-well plates with 300 \ensuremath{\mu}L after the cells (5 x10\ensuremath{^{6}} cells per millilitre) were developed as a monolayer also yielded using 0.25\% trypsin in a 0.03\% ethylene diamine tetra acetic acid liquid, before being exposed to R.P. at various doses (10{\textendash}300 \ensuremath{\mu}g/ml). 

The cells were taken out and given two PBS washes after being treated for 24 hours. Following the manufacturer's instructions, cells were dyed through Annexin V-FITC (Kit \#3 for Annexin V-FITC apoptosis, Invitrogen) also the Cell Quest Program was used to do FACS analysis of apoptosis.

\textbf{Investigation of cell growth}

HeLa and SiHa cells were planted in plates with 24 wells as multiple copies in an average cell density of 1 x 10\ensuremath{^{5}} tissues per millilitre. The cells were doused with R.P. at various doses (10, 100, 200 also 300\ensuremath{\mu}g/ml) and allowed to grow for 6, 12, in addition to 24 hours the following day. The trypan blue stain elimination technique was used to extract the cells and determine their viability. The cells are then 37 \ensuremath{^\circ}C humid atmosphere through 5\% CO\ensuremath{_{2}} incubation for 48 hours.

\textbf{Assay for colony development }

One x 10\ensuremath{^{3}} tissues per millilitre of cells were placed on plates with six wells. For a total of 24 hours, cell lines were exposed to R.P. at various concentrations: 10, 100, 200, and300 \ensuremath{\mu}g/ml. At 37 degrees Celsius and 5 percent CO\ensuremath{_{2}}, dishes were cultivated for a week. After being fixed with 4\% paraformaldehyde, the colonies were dyed with 0.5\% crystal violet \unskip~\cite{1984295:28380771}. 

Assay with soft agar Control HeLa as well asSiHa cells (5 x 10\ensuremath{^{3}} cells per millilitre), and in the media for culture, cells treated with R.P. (10{\textendash}300\ensuremath{\mu}g/ml) at various concentrations had been blended around 40 degrees Celsius through 0.35 percent of agarose (DNA level, GIBCOBRL, USA) as well as coagulated in a culture media above a layer containing 0.5 percent agarosethat had already coagulated for about 20 minutes at ambient temperature.

The experiment was conducted on 24 well plates. Colonies were directly imaged and also counted after ten days of incubation using a Carl Zeiss Axiovert 200M microscope.

\textbf{Cell Maintenance and Culture}

Penicillin (100 U~per millilitre), streptomycin (100 \ensuremath{\mu}g per millilitre), as well as amphotericin B (2.5 \ensuremath{\mu}g per millilitre) antibiotic solutions had been added to DMEM supplemented (grown in RPMI 1640 FA-deficient media) containing 10 percent FBS, L-glutamine, pure washing soda (Na\ensuremath{_{2}}CO\ensuremath{_{3}}), also the HeLawithSiHa lines cell. The lines of cells were grown and maintained at 37 degrees Celsius using an incubator that was humidified with 5 percent carbon-di-oxide environment (NBS Eppendorf, Germany). TPVG mixture (0.02\% trypsin, 0.02\% EDTA, as well as 0.05\% glucose with PBS) was used to separate the cell lines. After centrifugation, the viability of the cells was evaluated. A 24-well plate was seeded with an additional 50,000 cells per well and cultured for 24 hours in a 5\% CO\ensuremath{_{2}} environment. DMEM, FBS, pen strips, and trypsin were purchased from Himedia as reagent sources.

\% of viability = 100 times

\textbf{Evaluation of cytotoxicity (3-[4,5-dimethythiazol-2-yl]-assay using 2,5-diphenyl tetrazolium bromide}

\textbf{Cytotoxicity Examination Employing Direct Microscopy:}

In a reversed-phase dissimilarity culture tissue microscope (Olympus CKX41 featuring an Optika Pro5 CCD camera), all of the plate was viewed every twenty-four hours for up to seventy-two hours; also Photos were used to document microscopic studies.

As a sign of cytotoxicity, modifies in cell morphology similar to circulating or otherwise contraction, granulation, also vacuolization in the cytoplasm were taken into consideration.

\textbf{Cytotoxicity Assay Using the MTT Method: }

UsingHeLa cell lines, a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) testing has been carried out to assess the effects of the R.R.'s selectivity and cytotoxicity.[22]The control population did not receive any medicine, while tissues were grown at 37 degrees Celsius for around 24 hours.

Three millilitres of PBS were reconstituted with fifteen milligrams of MTT (Sigma, M-5655) and allowed to dissolve completely before filter sterilization.

For the anti-proliferative tests, successive dilutions of the trial formulations (10, 100, 200, also 300 \ensuremath{\mu }g per millilitre) were made in DMSO.After each passage, the trypsinized monolayer lines of cell cultivation, with a rise in cell density to 1.0 x 10\ensuremath{^{5}} tissues per millilitre utilizing the appropriate mediahaving10 percent FBS. The diluted cell solution was divided into 100\ensuremath{\mu }lportions and added to the 96-well microtiter-disc with 50,000 cells per well. A fractional monolayer was created after 24 hours; the excess fluid was removed, this monolayer was cleaned one time with a medium also 100 \ensuremath{\mu }ldrug doses were administered to the fractional monolayer using microtiter discs throughout several tests. 

The discs were subsequently grown over a period of 48 hours at a temperature of 37 degrees Celsius in an atmosphere containing five percent carbon dioxide. After the initial 24 hours of incubation, a specimen substance in the fines was eliminated, and each test and cell lines control well-received 30 \ensuremath{\mu}l of reconstituted MTT fluid. The plate was then quietly shaken fine, and it was then cultured over 4 hours at around 37 degrees Celsius with moistened 5 percent carbon-di-oxide. 200 \ensuremath{\mu}l of the MTT Solubilization Fluid DMSO were subsequently put into the wells for dissolving any Formosan crystal, following the cultured period, and gently combining the wells by pipetting up and down the supernatant.

The absorbance measurements were made with an effective wavelength of 540 nm was calculated employing a microplate reader. The formula used to calculate the proportion of development inhibition is as follows:

\% of viability =  (O.D. sample means/O.D. on average for the control group) x 100

Human carcinoma cell lines were tested for in vitro examinations to determine the R.P.'s cytotoxic action at dosages 10, 100, 200, also 300 \ensuremath{\mu }g per millilitre. Results showed that in different amounts, the R.P.'s have in-vitro anticancer activity against the HeLa with SiHacarcinoma cell line.

The Siddha formulation R.P. significantly inhibited the growth of the tested the HeLalines of cell, according to the current study's result analysis. Furthermore, the study's findings show that when the concentration of the trial medication R.P. increases, the percentage of HeLalines of cell viability decreases. In the MTT experiment, the lowest cell viability was found at an attention of 300 \ensuremath{\mu}g per millilitre, showing 36.24 \ensuremath{\pm}2.854\%. This was tracked by attention of 200 \ensuremath{\mu}g per millilitre, 100 \ensuremath{\mu}g per millilitre also 10 \ensuremath{\mu}g per millilitre, showing 52.86\ensuremath{\pm}3.014, 63.48\ensuremath{\pm}3.264, and 91.59 \ensuremath{\pm}3.386\% respectively. It was discovered that the equivalent IC50 assessment was 139.35\ensuremath{\pm} 5.863\ensuremath{\mu}g per millilitre. Figures~\ref{f-e5728c3909d9} and~\ref{f-479c5e7c04cf}  with Table~\ref{tw-1c81270be3d9}  both demonstrate this \unskip~\cite{1984295:28380773}.

\textbf{A review of pharmacology discussion }

HeLa as well as SiHa cell lines were tested for anticancer efficacy. Therefore, a novel way of justification that demonstrates the efficient anticancer action of R.P. is the investigation of pharmacological action using the HeLa as well as SiHa lines of cells \unskip~\cite{1984295:28380794}.

\textbf{Pharmaceutical Research}

It was discovered that the proportion of development inhibition rose as trial drug concentrations rose. The test sample's IC50 in the HeLa line cell was determined to be 100\ensuremath{\mu}g per millilitre. It proves that Figure~\ref{f-479c5e7c04cf} displays the medication dosage and the inhibition percentages of the HeLa cells following treatment with Rasa Parpam  concentrate. The MTT assay's outcome demonstrates that Rasa Parpam's I.C. dosage is 100 \ensuremath{\mu}g per millilitre. The viability of the HeLa cells declines with increasing doses. On the HeLa line cell, it was discovered that the percentage inhibition growth consistently rose with increasing Rasa Parpam  attentiveness up to 10\ensuremath{\mu}g per millilitre and that the I.C. assessment was 50 also the R-assessment was 1.436 [Table~\ref{tw-3f74366b1c9d}].

\textbf{Interpretation}

\textbf{Applying MTT to assess cytotoxic impact}

Yellow, water-solvable tetra zolium compound is referred to as MTT. Its MTT assay measures cytotoxicity. An enzyme found in the mitochondria of live organisms called succinate dehydrogenase breaks stetra zolium ring, turning MTT into an insolvable purple Formosan. As a result, the number of feasible cells frankly correlates with the quantity of Formosan generated.

Using succinate dehydrogenase to metabolically inhibit 3-(4, 5-dimethylthiazol-2-yl)-2, 5-difeniltetrazol (MTT), the test's outcomes are reported, which enables the assessment of mitochondrial treatment-processed tissues' functioning. This method is extensively used to evaluate cell survival also proliferation \unskip~\cite{1984295:28380787}.

Formazan production is inversely related to the number of live cells. The cell lines were free of any detectable bacterial or fungal contamination.

To ascertain the unique Siddha formulations Rasa Parpam is cytotoxic to the HeLa cells. Using an MTT test, the trial was screened at various concentrations to establish the IC50. The concentration of the trial specimen was represented on the X-axis; also the Y-axis was used to plot the percentage of cell feasibility

It was discovered that the proportion of inhibition growth rose as test medication concentrations rose. The trial specimen's IC50 in the HeLaline cell was determined to be 100 \ensuremath{\mu}g per millilitre. This reveals that Rasa Parpam, a Siddha medication, effectively combats anticancer.

Rasa Parpam was given for 24 hours at a range of dosages (10{\textendash}300 \ensuremath{\mu}g per millilitre of 5\% MEM). It was found that the number of cell lines decreased with dose and that 50\% fewer HeLa lines bacteria were observed at a dose of around 100\ensuremath{\mu}g per millilitre of extract than the typical control.

The Optical density of the therapy compared to the control was calculated to ascertain the proportion of cell feasibility.

At a wavelength of 570 nm, a spectrophotometer reads optical density. Comparative values are calculated using the 50\% growth inhibition (IC50) rate in cells that have been exposed to particular drugs. Results are tabularized in Table~\ref{tw-4a9b75959e56}.

\textbf{Anti-tumor action }

\textbf{Rasaparpam activated in the HeLa as well as SiHa cells Apoptosis}

Using a flow cytometry kit depends on the availability of Annexin V-FITC/propidium iodide apoptosis, cell line apoptosis was examined. The HeLa cells also SiHa cells were, in a nutshell, processed with R.P. (10, 100, 200 also 300 \ensuremath{\mu}g per millilitre), gathered, and twice cleaned with cold PBS with ice. After that, Annexin V-FITC with propidium iodide was used to color the mitochondria. A stream cytometry technique was used to assess apoptosis \unskip~\cite{1984295:28380769}.

\textbf{Interpretation}

Annexin V/PI connecting was employed in this study to assess the carcinoma lines tissue's apoptosis stimulated with R.P. The figure illustrates the treatment of the HeLa lines tissues with R.P. (10, 100, 200 also 300 \ensuremath{\mu}g per millilitre) for around 12 hours, the fraction on apoptotic line tissues considerably raised from3.92\%\ensuremath{\pm} 2.09\% - 22.86\% \ensuremath{\pm}3.01\%, 23.68\% \ensuremath{\pm}4.5\%, also 66.03\% \ensuremath{\pm}4.51\%. The proportions for apoptosis line tissues also SiHa lines cells after Rasa Parpam processing (10, 100, 200, and 300 \ensuremath{\mu}g per millilitre) for 24 hours showed considerable growth from 10.33\% 6.39\% to 38.92\% 12.39\%, 47.13\% 13.61\%, also 56.99\% 14.24\%. All of the earlier information showed that R.P. significantly changed the development pattern of the HeLa as well as the SiHatissues, which may be a good sign for determining whether or not it has antitumor effects on cervical carcinogenic line cells \unskip~\cite{1984295:28380767}.

\textbf{Outcomes}

When tested on pancreatic carcinogenic line cells HeLa cell lines R.R. had significant action. The presence of LDH demonstrated that R.P. was capable of killing pancreatic carcinogenic line cells. Finally, it was discovered that the synergistic effects of R.P.'s many chemicals had a considerable impact on carcinogenic cells \unskip~\cite{1984295:28380791}.

\textbf{Assay for lactate dehydrogenase}

In accordance with the kit's instructions, the integrity of the cell membrane was checked using LDH trial supplies (CytoTox 96{\textregistered} Non-radioactive Cytotoxicity Examination, Promega's Company). The wavelength of the absorbance at 490 nm has been determined with the Varioskan Flash Microplate Reader. A proportion of (trail-empty)/(positive-empty) is used to express an LDH seepage (\% of optimistic control), whereas positives are the spectral density of the positive-controlled cells, trial refers to cells that have been photographed to R.R., the spectral density of empty wells is known as blank \unskip~\cite{1984295:28380785}.
    
\section{Results and Discussion}
\textbf{Anticancer activity in-vitro}

The herbal-metallic Siddha medication (R.P.) was examined to determine whether it may be effective in treating cancer cells. HeLa, as well as SiHa Human pancreatic carcinoma tissues, were two separate human carcinoma cell lines against which the drug's in-vitro cytotoxicity was tested. As a control, the medium was employed. Different R.P. concentrations (10, 100, 200 also 300 \ensuremath{\mu}g per milliliter) were used to treat the cells. After receiving medication, HeLa cells displayed 20\% less cell viability relative to the medium-only control (IC50 values around 333.33 \ensuremath{\mu}g per millilitre).

At higher drug concentrations (300 \ensuremath{\mu}g per millilitre), cell feasibility diminished with rising R.P. concentrations also reached nearly 20\%. However, unlike pancreatic cells, the additional carcinoma tissues, 

He La tissues, did not exhibit a few appreciable outcomes(55\% lines cell feasibility at 300 \ensuremath{\mu}g per millilitre attentiveness) [Figure~\ref{f-479c5e7c04cf}]. There's a chance that RP includes one otherwise more substances that pancreatic carcinoma cells are especially vulnerable to more sensitive.

\textbf{Release action of Lactate dehydrogenase}

LDH is an enzyme that can be used as a proxy for tissue degradation and is found in a wide range of organisms, including plants also mammals. When HeLa alsoSiHaline cells were treated with R.P., dose-dependent action was seen in the LDH release evaluation. When both cells were exposed to R.P., investigative cytotoxicity was seen at levels ranging from 10 to 300 \ensuremath{\mu }g per milliliter. In comparison to controls, LDH seepage increased by 90\% in He La cells also by 55\% in Si Ha cells at 10 \ensuremath{\mu }g per millilitre concentrations, respectively. LDH was released more readily as R.P. concentrations rose. At 300 \ensuremath{\mu }g per milliliter, RPdisplay caused the release of LDH to be 95\% in HeLa cells and about 75\% in SiHatissues. [Figures~\ref{f-b7c49efdefeb} and~\ref{f-35869ddb308c}].
    
\section{Discussion}
Scientific validations had been presented for solitary of the "Rasa Parpam" formulations made with Siddha Herbo minerals. To support the anticancer potential of R.P. versus cervical cancer, physicochemical also elemental analyses, toxicological research, with pharmacological investigations have been conducted.

Researchers emphasize the significance and necessity of looking into any potential medicine interactions caused by natural goods because herbal therapies are well known. Through cell survival also enzymatic activity testing, we looked into the mercuric sulfide-based herbo-metallic preparation R.P., which showed significant anticancer action in a human pancreatic tumor line cell. Researchers have discovered R.P. have cytotoxic effects on cancer cells. 

R.P. may be used as a clinically effective anticancer medicine because of the multiple ways that normal and tumor cells responded to it in-vitro.] Another study found that R.P. was more effective against pancreatic carcinoma both in-vivo also in-vitro. According to the studies, R.P. may include one or otherwise more components that have a greater effect on pancreatic tumor cells. Several lines of cells, such as a HeLa as well as SiHahuman carcinoma tissue lines, R.P. showed cytotoxic activity by slowing causing the death of cell with proliferation in cells. According to current microscopic also spectroscopic techniques, herbal-metallic compounds turn a heavy, rigid metal, inflexible, abrasive powder to a thin, flexible, also silky powdery (Bhasma), with the macro-dimensioned nanoparticles are shrunk to their original nano-size (10{\textendash}50 nm, generally). Although our findings imply that R.P. did not generate any toxicity, it has yet to be conclusively proven that these mercury-containing herbal-metallic therapies having no adverse effects on the human body. Additionally, a current research asserted that R.R. can therefore be viewed as a potentially effective anticancer medicine. Scientific validations had been presented for one of the "Rasaparpam" formulations made with Siddha Herbo-minerals. To support the anticancer potential of R.P. versus cervical cancer, physicochemical also elemental analyses, with pharmacological studies have been conducted.

The chemical compounds in R.P. exhibit a wide range of pharmacological actions and are very physiologically active. In-vitro investigational representations of cancer have been used to study R.P. drug, which have significant anticancer action. The Hela lines cell, is each susceptible to the anticancer effects of R.P. 

This study finds that cancer cells have significant growth inhibition. Additionally, the most often used line cell for anticancer research comes from colon cancer. The MTT evaluation was a frequently used technique for cytotoxicity testing. The anticancer investigation of a traditional R.P. formulation is available. However, a number of other classical R.P. formulations remain undiscovered and need to be examined for their potential to treat cancer. Many synthetic pharmaceuticals are used to treat conditions like tumor, but they exhibit certain unfavorable negative consequences, so research has switched to natural variations of herbal medicines.

Environmental carcinogenic molecules, which have the propensity to promote mutation at some levels, are the primary cause of cancer. Eventually, uncontrolled growths as well as tumor development within the target organ or location result from sustained mitosis, the lineage of mutation substitute, and diffusion across. Common anticancer medications often work by maximizing the cell cycle to an apoptotic state to cause cytotoxicity. 

One of the most reliable techniques for confirming cell viability and determining how harmful the test medications will be to cells is the MTT assay. The MTT assay operates on the same basis as the calorimetry method. After incubation, a metabolic enzyme transforms the active live cell's Formosan stain, which is present, into 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide. What distinguishes actively separating live cells from those that are dead? After the following wash also incubation, the ratio of the pinkish-  By inducing the creation of reactive oxygen species (ROS), active cell growth may occasionally be stopped. Regulating the amount of nitric oxide is undoubtedly another strategy to activate the anticancer system.  Inhibiting angiogenesis, which prevents the growth of new blood vessels, is another frequent mechanism that underlies the anticancer effects of a substance. While researchers have concluded that potential lively ingredients in the formulation claim a flexible method of action that triggers cell division and slows the progression of the disease, the amount of DNA fragmentation and cell damage can be determined by the amount of LDH that has accumulated in the medium.

When tested on pancreatic carcinogenic line cells He La cells), R.R. had significant action. The presence of LDH demonstrated that R.P. was capable of killing pancreatic carcinogenic line cells. Finally, it was discovered that the synergistic effects of R.P.'s many chemicals had a considerable impact on carcinogenic cells.

The current study shows that when the concentration of the test drug R.P. increases, the percentage of HeLa line cell viability falls. The lowest cell viability was found at an attention of 300 \ensuremath{\mu}g per millilitre, showing 36.24 \ensuremath{\pm}2.854\%. This was tracked by attentions of 200 \ensuremath{\mu}g per millilitre, 100 \ensuremath{\mu}g per millilitre also 10 \ensuremath{\mu}g per millilitre, showing 52.86\ensuremath{\pm}3.014, 63.48\ensuremath{\pm}3.264, and 91.59 \ensuremath{\pm}3.386\% respectively. 

A significant indicator of a formulation's or active ingredient's ability to inhibit biochemical or metabolic function is the half-maximum inhibitory attentiveness (IC50). A drug's typical quantification of IC50, or the quantity needed to inhibit 50\% of the cell population, is determined via a usual dose-response curvature; the potency will increase as the value decreases. 

The results of the current invest R.P. was 139.35 \ensuremath{\pm} 5.863 \ensuremath{\mu}g/ml.

The morphological properties of membranes are examined by hematoxylin/eosin marking.

H/E marking was employed to look at morphological modifications, like modifications in the lines of cells, the membrane, elimination of membrane irregularity, also tissue contractions, regarded as indicators of apoptosis's early stages,

Cancer line cells treated with the I.C. dosage (100\ensuremath{\mu}g/ml) exhibit signs of apoptosis, but conventionally treated cells under the same conditions seemed unaltered.

The rational development of potential anticancer metallic-based medicines utilized in carcinoma treatment has received plenty of attention since the discovery of cisplatin's antitumor action.

The primary goals of these investigations are to identify novel metal complexes that may be likely to circumvent the drawbacks of currently used clinical medications, such as resistance, also other pharmacological shortcomings.

The annual series contains relevant article reviews everywhere, such as metallic ions in organic methods.

Inorganic chemistry in drugs can be broadly categorized into two groups: ligands, which are medicines that focus metallic ions in various ways, whether they are free or otherwise protein-bound, also metallic-based medicines with imaging mediums, where the system of activity is often significantly influenced by the primary metallic ion.

\textbf{Summary}

Due to its anticancer properties, the experimental medication Rasa Parpam was chosen from classical Tamil literature. Experts correctly identified also verified each element. Pharmacological research was finished. It demonstrated the HeLa line cell for anticancer actions, the HeLa line cell as well as the SiHa cell line for antitumor actions of Rasa Parpam for anti-oxidant actions, respectively. Outcomes also discussion provide critical validations to demonstrate the drug's potency. The study's summary and explanation of the synergistic relationship between all of the essential components and supporting activities are provided in the conclusion. Its preliminary validation for having anticancer properties was finished. The anticancer assets of cervical cancer were improved and guaranteed as a result. In order to fully comprehend the precise molecular systems of action, further detailed animal model investigations and human clinical trials are needed. It can be used to treat cervical cancer in all nations because of its safety and painlessness.


    
\section{Conclusion}
The process for making drugs and its methods for standardization made GMP clear. The AYUSH-assigned testing process for Parpam has been fully satisfied by the trial medicine R.P. It demonstrated the effectiveness and precision of Rasa Parpam manufacturing. Escherichia coli displayed considerable sensitivity to the test antibiotic, suggesting that R.P. exhibits broad-spectrum antibacterial action against the investigated pathogens. It can therefore be recognized as a possible treatment with cervical anticancer and anti-microbial responsively against this general cancer tract infection also would be a useful media in the administration of cervical cancer illnesses. The results of the physicochemical examination showed that the mineral substance was more valuable and greater bio-available. The existence of inorganic materials, which were discovered through tests for evaluating acid as well as basic radicals, favored this investigation. Rasa Parpam has undergone numerous instrumental tests to support its indication as a treatment for cervical cancer, including SEM, Raman, as well as FT-IR spectrum analysis all revealed the chemical make-up, operational clusters also constituent part dimension of the substance. It was also thought about if the test medicine might have anti-microbial properties. The anticancer cause on the HeLa lines cell, the antitumor result on the HeLa as well as SiHa lines cell support the pharmacological actions. The primary viewpoint of this research is justified by issues like security, effectiveness, long-term self-likeness, bioavailability, the availability of important elements, anions also cations, with minerals supporting the action. Scientific verification of the anticancer action is possible. The female population around the world would profit from its non-toxic anticancer effect. In both industrialized also at present, the greatest cause of death for women in underdeveloped nations are cervical cancer. India has a diverse range of plants and cultures, and it frequently uses more recent herbal therapeutics. Through its formulas, the Siddha medical system establishes cancer treatment. Siddha medications are typically risk-free also freed of significant side effects compared to anticancer medicines used today. Since R.P.'s particles are nanoscale in size, they will be swiftly absorbed. Inorganic nanoparticles have recently attracted increased concentration as possible diagnostic also therapeutic systems in the area of oncology. Inorganic ultra-tiny particles have shown promise in the detection and therapy of tumors in cultured tumor cells in test tubes. As a result, it could be useful in the cure of tumor. The most recent pharmaceutical investigations show that R.P. contains beneficial compounds. Upon completion of the pharmacology examinations, a clinical trial is needed to confirm the drug's safety and effectiveness in humans. According to the findings of the current investigation, Siddha formulation R.P. significantly inhibits the growth of the tested HeLa line cell. RP has shown potential studies on numerous in-vivo and in-vitro substances anticancer properties. The research reported on RP for anticancer activity is in preclinical phase. So further clinical trial, for reported  preclinical studies can be carried out. R.P., the formulation of cervical cancer has been reported for its anticancer activity. These results show that the human pancreatic tumor line cultures are highly susceptible to Rasa Parpam as determined by development inhibition also LDH liberation activities. According to the study, R.P. has plenty of potential as a pancreatic cancer anticancer medication.
    
\section{Acknowledgement}
I Would like to thank to my team from Shanmuga Siddha Clinic and Laboratories, Thanjavur-613006, Tamil Nadu - India.

\textbf{Funding Support}

No Funding Support.

\textbf{Conflicts of Interest}

No.
    

\bibliographystyle{unsrt}

\bibliography{\jobname}\vspace*{20pt} 
\begin{mdframed}[backgroundcolor=cpboxcolor,hidealllines=true,innerbottommargin=7pt,innerrightmargin=1pt,rightmargin=1pt,innerleftmargin=1pt,leftmargin=2pt,skipabove=1pt,innertopmargin=2pt,innerbottommargin=1pt,skipbelow=1pt]%
{\fontsize{8.5}{10}\selectfont\textbf{Copyright:}~\copyrightstmt}	
\end{mdframed}
        
\begin{mdframed}[backgroundcolor=citeboxcolor,hidealllines=true,innerbottommargin=7pt,innerrightmargin=4pt,rightmargin=4pt,innerleftmargin=2pt,leftmargin=2pt,skipabove=1pt,innertopmargin=2pt,innerbottommargin=4pt,skipbelow=2pt]%
{\fontsize{8.5}{10}\selectfont\textbf{Cite~this~article:}~\citeauthor.~\citetitle.\space\makeatletter\abbrvJournalTitle\ \@copyrightYear;\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi\ifx\@journalIssue\@empty\else(\@journalIssue)\fi:\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}.\makeatother}	
\end{mdframed}
\vskip-1.1pc

\vskip.5pc
{\includegraphics[width=5cm]{pharmasprings_logo.png}}
~\\
{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \makeatletter\@copyrightYear\makeatother\ Pharma Springs Publication.}

\end{document}
